374 related articles for article (PubMed ID: 26070547)
1. The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia.
Janhunen SK; Svärd H; Talpos J; Kumar G; Steckler T; Plath N; Lerdrup L; Ruby T; Haman M; Wyler R; Ballard TM
Psychopharmacology (Berl); 2015 Nov; 232(21-22):4059-83. PubMed ID: 26070547
[TBL] [Abstract][Full Text] [Related]
2. Comparing the effects of subchronic phencyclidine and medial prefrontal cortex dysfunction on cognitive tests relevant to schizophrenia.
McAllister KA; Mar AC; Theobald DE; Saksida LM; Bussey TJ
Psychopharmacology (Berl); 2015 Nov; 232(21-22):3883-97. PubMed ID: 26194915
[TBL] [Abstract][Full Text] [Related]
3. Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice.
Rajagopal L; Massey BW; Michael E; Meltzer HY
Psychopharmacology (Berl); 2016 Feb; 233(4):649-60. PubMed ID: 26558619
[TBL] [Abstract][Full Text] [Related]
4. Handling prevents and reverses cognitive deficits induced by sub-chronic phencyclidine in a model for schizophrenia in rats.
Landreth K; Burgess M; Watson L; Lorusso JM; Grayson B; Harte MK; Neill JC
Physiol Behav; 2023 May; 263():114117. PubMed ID: 36781093
[TBL] [Abstract][Full Text] [Related]
5. Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia.
McLean SL; Grayson B; Idris NF; Lesage AS; Pemberton DJ; Mackie C; Neill JC
Eur Neuropsychopharmacol; 2011 Apr; 21(4):333-43. PubMed ID: 20630711
[TBL] [Abstract][Full Text] [Related]
6. TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABA
Rajagopal L; Huang M; Michael E; Kwon S; Meltzer HY
Neuropsychopharmacology; 2018 Nov; 43(12):2468-2477. PubMed ID: 30093697
[TBL] [Abstract][Full Text] [Related]
7. Phencyclidine-induced cognitive impairments in repeated touchscreen visual reversal learning tests in rats.
Savolainen K; Ihalainen J; Hämäläinen E; Tanila H; Forsberg MM
Behav Brain Res; 2021 Apr; 404():113057. PubMed ID: 33316322
[TBL] [Abstract][Full Text] [Related]
8. PCP-based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments.
Castañé A; Santana N; Artigas F
Psychopharmacology (Berl); 2015 Nov; 232(21-22):4085-97. PubMed ID: 25943167
[TBL] [Abstract][Full Text] [Related]
9. Aerobic exercise improves memory and prevents cognitive deficits of relevance to schizophrenia in an animal model.
Mitsadali I; Grayson B; Idris NF; Watson L; Burgess M; Neill J
J Psychopharmacol; 2020 Jul; 34(7):695-708. PubMed ID: 32431225
[TBL] [Abstract][Full Text] [Related]
10. Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: A preliminary investigation.
McLean SL; Harte MK; Neill JC; Young AM
J Psychopharmacol; 2017 Jun; 31(6):660-666. PubMed ID: 28441905
[TBL] [Abstract][Full Text] [Related]
11. Postnatal Phencyclidine (PCP) as a Neurodevelopmental Animal Model of Schizophrenia Pathophysiology and Symptomatology: A Review.
Grayson B; Barnes SA; Markou A; Piercy C; Podda G; Neill JC
Curr Top Behav Neurosci; 2016; 29():403-428. PubMed ID: 26510740
[TBL] [Abstract][Full Text] [Related]
12. Re-evaluating the PCP challenge as a pre-clinical model of impaired cognitive flexibility in schizophrenia.
Fellini L; Kumar G; Gibbs S; Steckler T; Talpos J
Eur Neuropsychopharmacol; 2014 Nov; 24(11):1836-49. PubMed ID: 25300235
[TBL] [Abstract][Full Text] [Related]
13. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm.
Abdul-Monim Z; Reynolds GP; Neill JC
Behav Brain Res; 2006 May; 169(2):263-73. PubMed ID: 16500717
[TBL] [Abstract][Full Text] [Related]
14. Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration.
Elsworth JD; Groman SM; Jentsch JD; Valles R; Shahid M; Wong E; Marston H; Roth RH
Neuropharmacology; 2012 Mar; 62(3):1442-52. PubMed ID: 21875607
[TBL] [Abstract][Full Text] [Related]
15. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats.
Rodefer JS; Murphy ER; Baxter MG
Eur J Neurosci; 2005 Feb; 21(4):1070-6. PubMed ID: 15787711
[TBL] [Abstract][Full Text] [Related]
16. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
Neill JC; Barnes S; Cook S; Grayson B; Idris NF; McLean SL; Snigdha S; Rajagopal L; Harte MK
Pharmacol Ther; 2010 Dec; 128(3):419-32. PubMed ID: 20705091
[TBL] [Abstract][Full Text] [Related]
17. Synaptic biomarker reduction and impaired cognition in the sub-chronic PCP mouse model for schizophrenia.
Gigg J; McEwan F; Smausz R; Neill J; Harte MK
J Psychopharmacol; 2020 Jan; 34(1):115-124. PubMed ID: 31580184
[TBL] [Abstract][Full Text] [Related]
18. Investigating the long-term effect of subchronic phencyclidine-treatment on novel object recognition and the association between the gut microbiota and behavior in the animal model of schizophrenia.
Pyndt Jørgensen B; Krych L; Pedersen TB; Plath N; Redrobe JP; Hansen AK; Nielsen DS; Pedersen CS; Larsen C; Sørensen DB
Physiol Behav; 2015 Mar; 141():32-9. PubMed ID: 25545766
[TBL] [Abstract][Full Text] [Related]
19. Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT)1A-dependent mechanism.
Horiguchi M; Miyauchi M; Neugebauer NM; Oyamada Y; Meltzer HY
Behav Brain Res; 2016 Mar; 301():132-41. PubMed ID: 26342283
[TBL] [Abstract][Full Text] [Related]
20. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat.
Abdul-Monim Z; Reynolds GP; Neill JC
J Psychopharmacol; 2003 Mar; 17(1):57-65. PubMed ID: 12680740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
